Clinicopathological and molecular analyses of uterine carcinosarcomas using next-generation sequencing: A single-center experience

dc.authoridOz Puyan, Fulya/0000-0001-5853-0109;
dc.authorwosidOz Puyan, Fulya/A-7077-2018
dc.authorwosidPuyan, Fulya Oz/A-7804-2016
dc.authorwosidGenc Erdogan, Ezgi/ABM-0107-2022
dc.contributor.authorErdogan, Ezgi Genc
dc.contributor.authorYalta, Tuelin D.
dc.contributor.authorCan, Nuray
dc.contributor.authorSut, Necdet
dc.contributor.authorTastekin, Ebru
dc.contributor.authorUsta, Ufuk
dc.contributor.authorPuyan, Fulya Oz
dc.date.accessioned2024-06-12T11:08:41Z
dc.date.available2024-06-12T11:08:41Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground: Uterine carcinosarcomas (UCS) constitute 3-4% of all uterine malignancies and 16% of deaths caused due to uterine neoplasms. Aim: In this study, we aimed to perform DNA-based mutation analysis in 12 genes (KRAS, NRAS, EGFR, C-KIT, BRAF, PDGFRA, ALK, ERBB2, ERBB3, ESR1, RAF1, PIK3CA) to determine the molecular subtypes of UCS using next-generation sequencing (NGS) in patients with aggressive UCS and poor prognosis. We aimed to compare the results of our analysis with clinicopathological data to contribute to the development of targeted therapy approaches related to the molecular changes of UCS. Materials and Methods: In this study, we included 12 cases diagnosed with uterine carcinosarcomas and examined the changes in oncogenes that play a role in UCS pathogenesis. For the analysis of mutation, the clinicopathological data were compared with the variations in the DNA-based gene panel consisting of 12 genes and 1237 variants in the UCS using the NGS method. Results: EGFR mutation was found in 91.7% of the cases, mutation in 41.7%, PDGFRA mutation in 25%, KRAS and PIK3CA mutation in 16.7%, and C-KIT mutation in 8.3% of the cases. Although no statistical significance was found between the detected mutation and clinicopathological data, it was concluded that PDGFRA mutation might be associated with advanced-stage disease development. Conclusion: This study's findings regarding different molecular types of UCS and information on oncogenesis of UCS can provide inferences for targeted therapies in the future by identifying targetable mutations representing early oncogenic events and thereby contribute toward further studies on this subject.en_US
dc.description.sponsorshipTrakya University [2019/04]en_US
dc.description.sponsorshipThis work was supported by Research Fund of the Trakya University. Project Number: 2019/04.en_US
dc.identifier.doi10.4103/ijpm.ijpm_777_21
dc.identifier.endpage455en_US
dc.identifier.issn0377-4929
dc.identifier.issn0974-5130
dc.identifier.issue3en_US
dc.identifier.pmid37530323en_US
dc.identifier.scopus2-s2.0-85166031711en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage449en_US
dc.identifier.urihttps://doi.org/10.4103/ijpm.ijpm_777_21
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22520
dc.identifier.volume66en_US
dc.identifier.wosWOS:001044400000003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofIndian Journal Of Pathology And Microbiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMolecular Analysisen_US
dc.subjectMolecular Variationsen_US
dc.subjectMutationsen_US
dc.subjectNext-Generation Sequencingen_US
dc.subjectUterine Carcinosarcomaen_US
dc.subjectC-Kiten_US
dc.subjectExpressionen_US
dc.subjectOvarianen_US
dc.subjectTumorsen_US
dc.subjectComponentsen_US
dc.subjectHer-2/Neuen_US
dc.subjectSurvivalen_US
dc.subjectHer2/Neuen_US
dc.subjectTherapyen_US
dc.subjectMarkersen_US
dc.titleClinicopathological and molecular analyses of uterine carcinosarcomas using next-generation sequencing: A single-center experienceen_US
dc.typeArticleen_US

Dosyalar